Ranbaxy Granted Favorable Decision by the US Court of Appeals Regarding Marketing Exclusivity for Simvastatin 80mg
16th Nov 2006, 08:21 GMT
Decision has wide-ranging implications for Ranbaxy as well as other generic pharmaceutical manufacturers
Ranbaxy Granted Favorable Decision by the US Court of Appeals Regarding Marketing Exclusivity for Simvastatin 80mg related news:
- Teva, Ranbaxy exclusivity on generic Zocor confirmed — HomePage
- Court Backs Generic Drug Makers — WSJ.com: US Business
- Teva Says Generic Zocor Decision Upheld — Financial News News from StratCenter.com
- T-Mobile Pearl exclusivity 'til December 1: how ironclad is this? — BBHub
- California appeals court ruling on same-sex marriages goes to Supreme Court — The Earth Times Online Newspaper - Legal News
- Texas appeals court rejects treaty violation argument — KLTV - Local and National News
- San Francisco appeals gay marriage order (AP) — Yahoo! News: U.S. News
- Federal appeals court upholds Ohio abortion counseling provision — JURIST - Paper Chase
- A month after an appeals court ruled against same-sex marriage, ... — U.S. News on Yahoo! News Photos
- San Francisco Appeals Gay Marriage Order — Dayton Daily News National Headlines
Latest news from FDA News News from StratCenter.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting